India’s Drug Regulatory Authority to be based on US FDA Model

In the next three years, India would move towards setting up a drug regulatory authority on the model of the US FDA, the country

Cellworks in collaboration with Orchid on drug discovery

Cellworks Research India, the Bangalore-based research and development (R&D) wing of Cellworks Group Inc (California-headquartered company), has assisted Chennai-based Orchid Chemicals and Pharmaceuticals by providing system biology technology in carrying out ongoing New Chemical Entity (NCE) research programme.

Breakthrough in cardiac pharmacology

PhysioStim of France, a specialist in cardiac safety pharmacology, is setting up a new model for isolated cardiomyocytes, which will record all types of ionic currents and action potentials.

US based 3M is in talks with Indian pharma companies to license tech technologies

US-based $23-billion diversified technology firm 3M is in talks with top domestic pharma companies to licence drug delivery technologies.

IBM targets multi-billion $ health sector in India

IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.

IBM targets multi-billion $ health sector in India

IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.

IBM targets multi-billion $ health sector in India

IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.

Citi Venture Capital picks up 30% in Unimark

US-based private equity fund Citi Venture Capital (CVC) has picked up nearly 30% stake in Mumbai-based bulk drug maker Unimark Remedies for INR 113 crore. The transaction, one of the largest investments in the pharma sector in 2007 and CVC

Ranbaxy may dilute 60% in new R&D unit

Ranbaxy Laboratories may dilute up to 60% stake in its new research company, which will be formed by hiving off its R&D unit into a separate entity in 2008.

NPIL, Merck in research deal for cancer drugs

Nicholas Piramal (NPIL) has reportedly signed a research deal potentially worth a maximum revenue of USD 350 million with US pharmaceutical giant Merck & Co to carry out early discovery and development of two new cancer drugs, the two companies said on Monday.

India’s Manipal AcuNova acquires German firm Ecron

Clinical research firm Manipal AcuNova Ltd recently announced it has completed the acquisition of ECRON GmbH, Europe.

Orchid adopts Lorenz eCTD solution (docuBridge)

The LORENZ Life Sciences Group announced recently that Orchid Chemicals & Pharmaceuticals, located in Chennai, India has chosen docuBridge as its eCTD Publishing and Management solution.

NEWS REVIEW – BUSINESS

[This article was published in the November 2007 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]

News Review